Journal article

The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients

Anne Sofie Hogh Kolbaek Kjaer, Christel Rothe Brinkmann, Charles A Dinarello, Rikke Olesen, Lars Ostergaard, Ole Schmeltz Sogaard, Martin Tolstrup, Thomas Aagaard Rasmussen

AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015

Abstract

OBJECTIVE: To investigate the effect of the histone deacetylase inhibitor panobinostat on HIV-associated inflammation. DESIGN: Sub-study of a single-arm, phase I/II clinical trial. METHODS: HIV-infected adults on suppressive antiretroviral therapy received oral panobinostat 20 mg three times per week, every other week, for 8 weeks, that is, four cycles of treatment. Plasma levels of high-sensitivity C-reactive protein, matrix metalloproteinase 9, soluble CD40 ligand and interleukin-6 were determined using human ELISA kits. Soluble endothelia selectin (E-selectin) was measured by a multiplex immunoassay. Total monocyte count, phenotype changes on monocytes and monocyte histone acetylation wer..

View full abstract